CN110771766A - 用于儿童肠绞痛、腹泻、修复肠道的益生菌保健饮料 - Google Patents
用于儿童肠绞痛、腹泻、修复肠道的益生菌保健饮料 Download PDFInfo
- Publication number
- CN110771766A CN110771766A CN201911105557.0A CN201911105557A CN110771766A CN 110771766 A CN110771766 A CN 110771766A CN 201911105557 A CN201911105557 A CN 201911105557A CN 110771766 A CN110771766 A CN 110771766A
- Authority
- CN
- China
- Prior art keywords
- lactobacillus
- diarrhea
- colic
- intestinal
- probiotic
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 239000006041 probiotic Substances 0.000 title claims abstract description 51
- 235000018291 probiotics Nutrition 0.000 title claims abstract description 51
- 230000000529 probiotic effect Effects 0.000 title claims abstract description 26
- 210000001035 gastrointestinal tract Anatomy 0.000 title claims abstract description 22
- 208000004998 Abdominal Pain Diseases 0.000 title claims abstract description 18
- 206010012735 Diarrhoea Diseases 0.000 title claims abstract description 18
- 208000002881 Colic Diseases 0.000 title claims abstract description 17
- 235000013361 beverage Nutrition 0.000 title claims abstract description 17
- 230000000968 intestinal effect Effects 0.000 title abstract description 17
- 241001608472 Bifidobacterium longum Species 0.000 claims abstract description 16
- 241000218588 Lactobacillus rhamnosus Species 0.000 claims abstract description 16
- 229940009291 bifidobacterium longum Drugs 0.000 claims abstract description 16
- 241000901050 Bifidobacterium animalis subsp. lactis Species 0.000 claims abstract description 15
- 241000186604 Lactobacillus reuteri Species 0.000 claims abstract description 15
- 229940009289 bifidobacterium lactis Drugs 0.000 claims abstract description 15
- 229940001882 lactobacillus reuteri Drugs 0.000 claims abstract description 15
- 240000001046 Lactobacillus acidophilus Species 0.000 claims abstract description 13
- 235000013956 Lactobacillus acidophilus Nutrition 0.000 claims abstract description 13
- 240000006024 Lactobacillus plantarum Species 0.000 claims abstract description 13
- 235000013965 Lactobacillus plantarum Nutrition 0.000 claims abstract description 13
- 230000036541 health Effects 0.000 claims abstract description 13
- 229940039695 lactobacillus acidophilus Drugs 0.000 claims abstract description 13
- 229940072205 lactobacillus plantarum Drugs 0.000 claims abstract description 13
- 241000894006 Bacteria Species 0.000 claims description 11
- 230000008439 repair process Effects 0.000 claims description 7
- 230000009286 beneficial effect Effects 0.000 abstract description 3
- 230000002496 gastric effect Effects 0.000 abstract description 2
- 230000036039 immunity Effects 0.000 description 4
- 230000001737 promoting effect Effects 0.000 description 4
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 3
- 238000010521 absorption reaction Methods 0.000 description 3
- HVYWMOMLDIMFJA-DPAQBDIFSA-N cholesterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CCCC(C)C)[C@@]1(C)CC2 HVYWMOMLDIMFJA-DPAQBDIFSA-N 0.000 description 3
- 201000010099 disease Diseases 0.000 description 3
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 3
- 235000013305 food Nutrition 0.000 description 3
- 230000002401 inhibitory effect Effects 0.000 description 3
- 239000007788 liquid Substances 0.000 description 3
- 229940057917 medium chain triglycerides Drugs 0.000 description 3
- 208000024891 symptom Diseases 0.000 description 3
- 241000186000 Bifidobacterium Species 0.000 description 2
- XEEYBQQBJWHFJM-UHFFFAOYSA-N Iron Chemical compound [Fe] XEEYBQQBJWHFJM-UHFFFAOYSA-N 0.000 description 2
- 208000002193 Pain Diseases 0.000 description 2
- 230000003115 biocidal effect Effects 0.000 description 2
- 230000015572 biosynthetic process Effects 0.000 description 2
- 238000003745 diagnosis Methods 0.000 description 2
- 210000004347 intestinal mucosa Anatomy 0.000 description 2
- JVTAAEKCZFNVCJ-UHFFFAOYSA-N lactic acid Chemical compound CC(O)C(O)=O JVTAAEKCZFNVCJ-UHFFFAOYSA-N 0.000 description 2
- 239000003921 oil Substances 0.000 description 2
- 235000019198 oils Nutrition 0.000 description 2
- 230000001717 pathogenic effect Effects 0.000 description 2
- 230000001105 regulatory effect Effects 0.000 description 2
- 150000004671 saturated fatty acids Chemical class 0.000 description 2
- 239000002904 solvent Substances 0.000 description 2
- 239000000126 substance Substances 0.000 description 2
- 238000002560 therapeutic procedure Methods 0.000 description 2
- 239000003053 toxin Substances 0.000 description 2
- UFTFJSFQGQCHQW-UHFFFAOYSA-N triformin Chemical compound O=COCC(OC=O)COC=O UFTFJSFQGQCHQW-UHFFFAOYSA-N 0.000 description 2
- AKXKFZDCRYJKTF-UHFFFAOYSA-N 3-Hydroxypropionaldehyde Chemical compound OCCC=O AKXKFZDCRYJKTF-UHFFFAOYSA-N 0.000 description 1
- ZCYVEMRRCGMTRW-UHFFFAOYSA-N 7553-56-2 Chemical compound [I] ZCYVEMRRCGMTRW-UHFFFAOYSA-N 0.000 description 1
- OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 description 1
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical group [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 description 1
- 208000024172 Cardiovascular disease Diseases 0.000 description 1
- 206010010774 Constipation Diseases 0.000 description 1
- 206010011469 Crying Diseases 0.000 description 1
- 241000192125 Firmicutes Species 0.000 description 1
- 241000233866 Fungi Species 0.000 description 1
- 201000010538 Lactose Intolerance Diseases 0.000 description 1
- 206010028980 Neoplasm Diseases 0.000 description 1
- 240000004808 Saccharomyces cerevisiae Species 0.000 description 1
- 210000001015 abdomen Anatomy 0.000 description 1
- 230000001154 acute effect Effects 0.000 description 1
- 238000009098 adjuvant therapy Methods 0.000 description 1
- 239000003242 anti bacterial agent Substances 0.000 description 1
- 230000000844 anti-bacterial effect Effects 0.000 description 1
- 230000003064 anti-oxidating effect Effects 0.000 description 1
- 229940088710 antibiotic agent Drugs 0.000 description 1
- 244000052616 bacterial pathogen Species 0.000 description 1
- 230000036772 blood pressure Effects 0.000 description 1
- 229910052791 calcium Inorganic materials 0.000 description 1
- 239000011575 calcium Substances 0.000 description 1
- 230000009702 cancer cell proliferation Effects 0.000 description 1
- 231100000357 carcinogen Toxicity 0.000 description 1
- 239000003183 carcinogenic agent Substances 0.000 description 1
- 230000032823 cell division Effects 0.000 description 1
- 235000012000 cholesterol Nutrition 0.000 description 1
- 239000003240 coconut oil Substances 0.000 description 1
- 235000019864 coconut oil Nutrition 0.000 description 1
- 150000001875 compounds Chemical class 0.000 description 1
- 230000008602 contraction Effects 0.000 description 1
- 238000000354 decomposition reaction Methods 0.000 description 1
- 230000013872 defecation Effects 0.000 description 1
- 230000007547 defect Effects 0.000 description 1
- 235000013367 dietary fats Nutrition 0.000 description 1
- 239000003995 emulsifying agent Substances 0.000 description 1
- 230000002708 enhancing effect Effects 0.000 description 1
- 239000000686 essence Substances 0.000 description 1
- 230000002349 favourable effect Effects 0.000 description 1
- 206010016766 flatulence Diseases 0.000 description 1
- 239000002778 food additive Substances 0.000 description 1
- 235000013373 food additive Nutrition 0.000 description 1
- 230000008014 freezing Effects 0.000 description 1
- 238000007710 freezing Methods 0.000 description 1
- 210000004211 gastric acid Anatomy 0.000 description 1
- 235000020256 human milk Nutrition 0.000 description 1
- 210000004251 human milk Anatomy 0.000 description 1
- 230000007062 hydrolysis Effects 0.000 description 1
- 238000006460 hydrolysis reaction Methods 0.000 description 1
- 230000007365 immunoregulation Effects 0.000 description 1
- 230000006872 improvement Effects 0.000 description 1
- 208000015181 infectious disease Diseases 0.000 description 1
- 208000028774 intestinal disease Diseases 0.000 description 1
- 230000007413 intestinal health Effects 0.000 description 1
- 239000011630 iodine Substances 0.000 description 1
- 229910052740 iodine Inorganic materials 0.000 description 1
- 229910052742 iron Inorganic materials 0.000 description 1
- 239000004310 lactic acid Substances 0.000 description 1
- 235000014655 lactic acid Nutrition 0.000 description 1
- 239000011159 matrix material Substances 0.000 description 1
- 150000004667 medium chain fatty acids Chemical class 0.000 description 1
- 238000000034 method Methods 0.000 description 1
- 235000013336 milk Nutrition 0.000 description 1
- 239000008267 milk Substances 0.000 description 1
- 210000004080 milk Anatomy 0.000 description 1
- 230000036651 mood Effects 0.000 description 1
- 235000015097 nutrients Nutrition 0.000 description 1
- 230000009965 odorless effect Effects 0.000 description 1
- 230000003647 oxidation Effects 0.000 description 1
- 238000007254 oxidation reaction Methods 0.000 description 1
- 235000019865 palm kernel oil Nutrition 0.000 description 1
- 239000003346 palm kernel oil Substances 0.000 description 1
- 230000001314 paroxysmal effect Effects 0.000 description 1
- 244000052769 pathogen Species 0.000 description 1
- 230000008855 peristalsis Effects 0.000 description 1
- 239000000049 pigment Substances 0.000 description 1
- 229940068196 placebo Drugs 0.000 description 1
- 239000000902 placebo Substances 0.000 description 1
- 238000002360 preparation method Methods 0.000 description 1
- 230000002265 prevention Effects 0.000 description 1
- 239000002994 raw material Substances 0.000 description 1
- 229920006395 saturated elastomer Polymers 0.000 description 1
- 235000003441 saturated fatty acids Nutrition 0.000 description 1
- 235000021391 short chain fatty acids Nutrition 0.000 description 1
- 150000004666 short chain fatty acids Chemical class 0.000 description 1
- 210000002460 smooth muscle Anatomy 0.000 description 1
- 239000003549 soybean oil Substances 0.000 description 1
- 235000012424 soybean oil Nutrition 0.000 description 1
- 230000001225 therapeutic effect Effects 0.000 description 1
- 231100000765 toxin Toxicity 0.000 description 1
- 108700012359 toxins Proteins 0.000 description 1
- 210000004881 tumor cell Anatomy 0.000 description 1
- 235000021122 unsaturated fatty acids Nutrition 0.000 description 1
- 150000004670 unsaturated fatty acids Chemical class 0.000 description 1
- 235000013343 vitamin Nutrition 0.000 description 1
- 239000011782 vitamin Substances 0.000 description 1
- 229940088594 vitamin Drugs 0.000 description 1
- 229930003231 vitamin Natural products 0.000 description 1
- 150000003722 vitamin derivatives Chemical class 0.000 description 1
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L2/00—Non-alcoholic beverages; Dry compositions or concentrates therefor; Their preparation
- A23L2/38—Other non-alcoholic beverages
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L2/00—Non-alcoholic beverages; Dry compositions or concentrates therefor; Their preparation
- A23L2/52—Adding ingredients
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
- A23L33/115—Fatty acids or derivatives thereof; Fats or oils
- A23L33/12—Fatty acids or derivatives thereof
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
- A23L33/135—Bacteria or derivatives thereof, e.g. probiotics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/66—Microorganisms or materials therefrom
- A61K35/74—Bacteria
- A61K35/741—Probiotics
- A61K35/744—Lactic acid bacteria, e.g. enterococci, pediococci, lactococci, streptococci or leuconostocs
- A61K35/745—Bifidobacteria
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/66—Microorganisms or materials therefrom
- A61K35/74—Bacteria
- A61K35/741—Probiotics
- A61K35/744—Lactic acid bacteria, e.g. enterococci, pediococci, lactococci, streptococci or leuconostocs
- A61K35/747—Lactobacilli, e.g. L. acidophilus or L. brevis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/12—Antidiarrhoeals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2002/00—Food compositions, function of food ingredients or processes for food or foodstuffs
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Mycology (AREA)
- Engineering & Computer Science (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Public Health (AREA)
- Nutrition Science (AREA)
- Microbiology (AREA)
- Polymers & Plastics (AREA)
- Food Science & Technology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Organic Chemistry (AREA)
- General Chemical & Material Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Molecular Biology (AREA)
- Epidemiology (AREA)
- Pain & Pain Management (AREA)
- Rheumatology (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Coloring Foods And Improving Nutritive Qualities (AREA)
Abstract
本发明提供一种用于儿童肠绞痛、腹泻、修复肠道的的益生菌保健饮料，包括混合益生菌和MCT，所述混合益生菌由植物乳杆菌N13、长双歧杆菌BL21、鼠李糖乳杆菌LRa05、嗜酸乳杆菌、乳双歧杆菌、罗伊氏乳杆菌组成，其质量百分比为10‑40%植物乳杆菌N13、5‑30%长双歧杆菌BL21、10‑40%鼠李糖乳杆菌LRa05、1‑15%嗜酸乳杆菌、5‑30%乳双歧杆菌、15‑55%罗伊氏乳杆菌。本发明选用的乳双歧杆菌是婴儿出生后最先在肠内定植并占优势菌种，有益于其胃肠道健康。
Description
技术领域
本发明属于益生菌保健品技术领域，具体涉及一种用于儿童肠绞痛、腹泻、修复肠道的益生菌保健饮料。
背景技术
肠绞痛是指有些小婴儿会出现突然性大声哭叫，可持续几小时，也可阵发性发作。哭时婴儿面部渐红，口周苍白，腹部胀而紧张，双腿向上蜷起，双足发凉，双手紧握，抱哄喂奶都不能缓解，而最终以哭得力竭、排气或排便而停止，这种现象通常称为婴儿肠绞痛。这是由于婴儿肠壁平滑肌阵阵强烈收缩或肠胀气引起的疼痛，是小儿急性腹痛中最常见的一种。虽然肠绞痛不是疾病，并能够在半岁左右自愈，但它严重影响了婴儿的情绪、睡眠和生长发育，也扰乱了家长的作息时间。
儿童由于本身的生理特点和疾病的影响，肠道中微生态平衡十分脆弱，成为其发生腹泻的内在因素，抗生素的广泛使用及普遍存在的联合用药，加上用药时间长，是导致抗生素相关性腹泻上升的外在因素。由于新生儿所特有的对病原易感性和感染后表现出非特异性免疫的特点，大多数情况下临床医生很难准确把握应用抗生素治疗指征和预防指征，因而与抗生素治疗相关所导致的肠道菌群失调腹泻日渐增多。
发明内容
针对现有技术中的不足之处，本发明提供一种用于儿童肠绞痛、腹泻、修复肠道的益生菌保健饮料。
为了达到上述目的，本发明技术方案如下：
用于儿童肠绞痛、腹泻、修复肠道的益生菌保健饮料，包括混合益生菌和MCT，所述混合益生菌由植物乳杆菌N13、长双歧杆菌BL21、鼠李糖乳杆菌LRa05、嗜酸乳杆菌、乳双歧杆菌、罗伊氏乳杆菌组成，其质量百分比为10-40%植物乳杆菌N13、5-30%长双歧杆菌BL21、10-40%鼠李糖乳杆菌LRa05、1-15%嗜酸乳杆菌、5-30%乳双歧杆菌、15-55%罗伊氏乳杆菌。
进一步的，所述混合益生菌中各组成菌群的质量百分比为20%植物乳杆菌N13、10%长双歧杆菌BL21、20%鼠李糖乳杆菌LRa05、5%嗜酸乳杆菌、10%乳双歧杆菌、35%罗伊氏乳杆菌。
进一步的，所述混合益生菌活菌量为（2~3）×1010 CFU/g。
进一步的，所述混合益生菌和MCT的质量比为（0.75 - 1）:10。作为优选，质量比为0.8167:10。
进一步的，所述益生菌保健饮料每10mL中含有10gMCT。
本发明的原料：
（1）植物乳杆菌：具有很多的保健作用，如：有一定的免疫调节作用；对致病菌有抑制作用；降低血清胆固醇含量和预防心血管疾病；维持肠道内菌群平衡；促进营养物质吸收；缓解乳糖不耐症；抑制肿瘤细胞的形成等；
（2）长双歧杆菌：属于双歧杆菌属中的一种细菌：长双歧杆菌取自健康人体肠道，筛选出完全适合人体之菌株，是对人体有益的一种菌种；使用于一般食品类的长双歧杆菌，具有调节肠道健康的功效；
（3）鼠李糖乳杆菌：具有高效降胆固醇，促进细胞分裂，可起到调节肠道菌群、预防和治疗腹泻、排除毒素、预防龋齿、提高机体免疫力及抗癌等重要的生理保健功能；
（4）嗜酸乳杆菌：具有降血压；促进钙铁吸收；调整肠道菌群；抑制癌细胞增殖；增强免疫力；改善睡眠；抗氧化等作用；
（5）乳双歧杆菌：可以通过调整肠道菌群，并通过产生乙酸、乳酸等短链脂肪酸来抑制肠道腐败菌的生长和有毒代谢产物的形成，刺激肠蠕动，从而减少水分的过度吸收而缓解便秘症状；可通过调整肠道正常菌群，抑制肠道许多腐败菌生长，从而减少一些肠源性致癌物的产生；
（6）罗伊氏乳杆菌：对肠黏膜具有很强的黏附能力，可改善肠道菌群分布，拮抗有害菌定植，避免罹患肠道疾病；罗伊氏乳杆菌能产生一种被称为“罗伊氏菌素(Reuterin)”的非蛋白质类广谱抗菌物质，能广泛抑制革兰氏阳性菌、革兰氏阴性菌、酵母、真菌和病原虫等的生长。罗伊氏乳杆菌益生菌制剂可改善人体机能，提高免疫力从而促进人体健康；
（7）MCT：是中链甘油三酯（Medium Chain Triglycerides）的简称，是由碳链长度6-12的饱和中链脂肪酸组成的甘油三酯。医药行业中常用作溶剂、载体和乳化剂，也可以作为食品行业中香精、色素和维生素的溶剂，其具有不易被胃酸分解，易在肠道中水解的特性。天然存在于棕榈仁油、椰子油等食品和母乳中，是膳食脂肪的来源之一。作为食品添加剂，中链甘油三酯仅由饱和脂肪酸构成，凝固点低，室温下为液体，粘度小。与大豆油比较，完全是无臭、无色的透明液体。与普通的油脂和氢化油脂相比，中链甘油三酯不饱和脂肪酸的含量极低，氧化稳定性非常好，其碘值不超过0.5，MCT在高温和低温下特别稳定。
有益效果：本发明选用的乳双歧杆菌是婴儿出生后最先在肠内定植并占优势菌种，有益于其胃肠道健康。而鼠李糖乳杆菌在婴儿肠黏膜上的黏着率明显高于其他菌株，有利于其在肠道上的定植。有资料表明：添加鼠李糖乳杆菌，可提高双歧杆菌在婴儿体内的定植。适合婴幼儿服用，服用本发明的益生菌保健饮料，肠绞痛、腹泻、修复肠道症状缓解更快，更好地减轻病人痛苦。
具体实施方式
以下参照具体的实施例来说明本发明。本领域技术人员能够理解，这些实施例仅用于说明本发明，其不以任何方式限制本发明的范围。
实施例1
用于儿童肠绞痛、腹泻、修复肠道的益生菌保健饮料，每10mL益生菌保健饮料中含有10gMCT和0.8167g混合益生菌，混合益生菌由质量百分比为20%植物乳杆菌N13、10%长双歧杆菌BL21、20%鼠李糖乳杆菌LRa05、5%嗜酸乳杆菌、10%乳双歧杆菌、35%罗伊氏乳杆菌组成。混合益生菌活菌量为3×1010 CFU/g。
实施例2
用于儿童肠绞痛、腹泻、修复肠道的益生菌保健饮料，每10mL益生菌保健饮料中含有10gMCT和0.8167g混合益生菌，混合益生菌由质量百分比为40%植物乳杆菌N13、5%长双歧杆菌BL21、10%鼠李糖乳杆菌LRa05、10%嗜酸乳杆菌、5%乳双歧杆菌、30%罗伊氏乳杆菌组成。混合益生菌活菌量为2.5×1010 CFU/g。
实施例3
用于儿童肠绞痛、腹泻、修复肠道的益生菌保健饮料，每10mL益生菌保健饮料中含有10gMCT和0.8167g混合益生菌，混合益生菌由质量百分比为10%植物乳杆菌N13、18%长双歧杆菌BL21、12%鼠李糖乳杆菌LRa05、15%嗜酸乳杆菌、30%乳双歧杆菌、15%罗伊氏乳杆菌组成。混合益生菌活菌量为2×1010 CFU/g。
实施例4
用于儿童肠绞痛、腹泻、修复肠道的益生菌保健饮料，每10mL益生菌保健饮料中含有10gMCT和0.8167g混合益生菌，混合益生菌由质量百分比为10%植物乳杆菌N13、30%长双歧杆菌BL21、40%鼠李糖乳杆菌LRa05、1%嗜酸乳杆菌、5%乳双歧杆菌、15%罗伊氏乳杆菌组成。混合益生菌活菌量为2.8×1010 CFU/g。
实验观察
儿童医院2015年-2018年，随机抽取有肠绞痛、腹泻、修复肠道的儿童150例。观察组120例（实施例1-4各30例），对照组30例，两组病情无明显差异。其中观察组120例使用本发明的益生菌保健饮料辅助治疗；对照组30例中使用本发明的益生菌保健饮料作为安慰剂。
治疗方法：观察组于初诊当天服用，每日1次，每次25g，连续使用时间15-30日至下次复诊。对照组同上。观察两组的改善情况。
治疗结果
通过上表，整理上观察可知：一周内，观察组120例中病情情况得到缓解或改善103例(85.8%)，对照组30例中得到缓解或改善18例(60%)。服用本发明的益生菌保健饮料，症状缓解更快，更好地减轻病人痛苦。
Claims (6)
1.用于儿童肠绞痛、腹泻、修复肠道的的益生菌保健饮料，其特征在于：包括混合益生菌和MCT，所述混合益生菌由植物乳杆菌N13、长双歧杆菌BL21、鼠李糖乳杆菌LRa05、嗜酸乳杆菌、乳双歧杆菌、罗伊氏乳杆菌组成，其质量百分比为10-40%植物乳杆菌N13、5-30%长双歧杆菌BL21、10-40%鼠李糖乳杆菌LRa05、1-15%嗜酸乳杆菌、5-30%乳双歧杆菌、15-55%罗伊氏乳杆菌。
2.如权利要求1所述的用于儿童肠绞痛、腹泻、修复肠道的的益生菌保健饮料，其特征在于，所述混合益生菌中各组成菌群的质量百分比为20%植物乳杆菌N13、10%长双歧杆菌BL21、20%鼠李糖乳杆菌LRa05、5%嗜酸乳杆菌、10%乳双歧杆菌、35%罗伊氏乳杆菌。
3.如权利要求1所述的用于儿童肠绞痛、腹泻、修复肠道的的益生菌保健饮料，其特征在于，所述混合益生菌活菌量为（2~3）×1010 CFU/g。
4.如权利要求1所述的用于儿童肠绞痛、腹泻、修复肠道的的益生菌保健饮料，其特征在于，所述混合益生菌和MCT的质量比为（0.75 - 1）:10。
5.如权利要求4所述的用于儿童肠绞痛、腹泻、修复肠道的的益生菌保健饮料，其特征在于，所述混合益生菌和MCT的质量比为0.8167:10。
6.如权利要求1所述的用于儿童肠绞痛、腹泻、修复肠道的的益生菌保健饮料，其特征在于，所述益生菌保健饮料每10mL中含有10gMCT。
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201911105557.0A CN110771766A (zh) | 2019-11-13 | 2019-11-13 | 用于儿童肠绞痛、腹泻、修复肠道的益生菌保健饮料 |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201911105557.0A CN110771766A (zh) | 2019-11-13 | 2019-11-13 | 用于儿童肠绞痛、腹泻、修复肠道的益生菌保健饮料 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN110771766A true CN110771766A (zh) | 2020-02-11 |
Family
ID=69390739
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN201911105557.0A Pending CN110771766A (zh) | 2019-11-13 | 2019-11-13 | 用于儿童肠绞痛、腹泻、修复肠道的益生菌保健饮料 |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN110771766A (zh) |
Cited By (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN113151056A (zh) * | 2021-03-18 | 2021-07-23 | 仙乐健康科技股份有限公司 | 益生菌组合物、其制备方法和用途 |
| CN113615838A (zh) * | 2020-05-06 | 2021-11-09 | 宏浚实业有限公司 | 用于改善胃肠道健康的益生菌复合物 |
| US20220002664A1 (en) * | 2020-03-04 | 2022-01-06 | Lactomason Co., Ltd. | Lactobacillus reuteri lm1071 from breast milk having high safety and intestine adhesive property, and composition comprising the strain or its culture fluid |
Citations (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN106692204A (zh) * | 2017-03-10 | 2017-05-24 | 泰安大凡神农制药有限公司 | 一种缓解或改善盆腔炎症的益生菌组合物及其制备方法 |
-
2019
- 2019-11-13 CN CN201911105557.0A patent/CN110771766A/zh active Pending
Patent Citations (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN106692204A (zh) * | 2017-03-10 | 2017-05-24 | 泰安大凡神农制药有限公司 | 一种缓解或改善盆腔炎症的益生菌组合物及其制备方法 |
Non-Patent Citations (3)
| Title |
|---|
| 吴立新，张声生: "双歧杆菌四联活菌片联合用药对小儿非感染性腹泻的疗效及血清中IL-6、IL-17表达影响研究", 《重庆医学》 * |
| 宋茂清: "《益生剂及其功效》", 30 November 2018, 科学技术文献出版社 * |
| 梅奥营养（广西）卢绍欣: "梅奥MAYO营养滴剂系列简介", 《美篇HTTPS://WWW.MEIPIAN.CN/2EQIT8FF》 * |
Cited By (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20220002664A1 (en) * | 2020-03-04 | 2022-01-06 | Lactomason Co., Ltd. | Lactobacillus reuteri lm1071 from breast milk having high safety and intestine adhesive property, and composition comprising the strain or its culture fluid |
| CN113615838A (zh) * | 2020-05-06 | 2021-11-09 | 宏浚实业有限公司 | 用于改善胃肠道健康的益生菌复合物 |
| CN113151056A (zh) * | 2021-03-18 | 2021-07-23 | 仙乐健康科技股份有限公司 | 益生菌组合物、其制备方法和用途 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN111728111B (zh) | 一种缓解焦虑或抑郁的益生菌组合物及其应用 | |
| Sen | Role of probiotics in health and disease–A review | |
| TWI494114B (zh) | 鼠李醣乳酸桿菌gg(lgg)於治療、預防或減輕全身性發炎之用途 | |
| US8529887B2 (en) | Probiotics in a pre- and/or post surgical environment | |
| CN112716982B (zh) | 含乳酸菌的组合物及其用途 | |
| CN102770145A (zh) | 包含益生菌的手术和创伤患者专用医学营养 | |
| RU2012122064A (ru) | Питательные композиции, содержащие лактоферрин и приобиотики, и наборы из их частей | |
| WO2007140621A1 (en) | Probiotic compositions and uses thereof | |
| CN110771766A (zh) | 用于儿童肠绞痛、腹泻、修复肠道的益生菌保健饮料 | |
| NZ550501A (en) | Use of a fermentation product of propionic acid bacterium for treating inflammatory bowel diseases | |
| CN111004733A (zh) | 一种具有缓解便秘功能的凝结芽孢杆菌复合微生态制剂 | |
| CN110679813A (zh) | 一种用于减重的益生菌保健饮料 | |
| CN111557404A (zh) | 助消化益生菌固体饮料及其制备方法 | |
| CN110692885A (zh) | 一种用于缓解便秘的益生菌保健饮料 | |
| CN108283285A (zh) | 一种糖尿病的理疗保健食品 | |
| CN100482104C (zh) | 一种乳酸菌口服液的制备方法 | |
| CN106974262B (zh) | 肠道益生杆菌在治疗和预防肥胖及其相关疾病中的应用 | |
| CN103918792A (zh) | 一种木糖醇益生菌羊奶片及其制备方法 | |
| CN111034891A (zh) | 一种含益生菌组合物的固体饮料及其制备方法 | |
| CN102742653B (zh) | 一种健脑安神益生菌羊奶片及其制备方法 | |
| Onyenweaku et al. | Research Article Health Benefits of Probiotics | |
| US9826766B2 (en) | Use of polysaccharides for the intestinal well-being of nursing infants and/or infants | |
| CN103918795A (zh) | 一种茶多酚益生菌羊奶片及其制备方法 | |
| CN102754695A (zh) | 一种牛蒡益生菌羊奶片及其制备方法 | |
| CN102742654B (zh) | 一种养颜美容益生菌羊奶片及其制备方法 |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PB01 | Publication | ||
| PB01 | Publication | ||
| SE01 | Entry into force of request for substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| RJ01 | Rejection of invention patent application after publication |
Application publication date: 20200211 |
|
| RJ01 | Rejection of invention patent application after publication |